CANbridge Pharmaceuticals Inc., and WuXi Biologics (2269. HK), jointly announced an expansion of their rare disease partnership to enable CANbridge to discover, develop and commercialize four additional drug candidates. These new candidates target rare genetic chronic diseases. According to the agreement, CANbridge has an exclusive regional or global rights for these therapies. WuXi Biologics will receive upfront, milestone payments and royalties. WuXi Biologics will also be the exclusive clinical supplier and primary commercial supplier for all these programs.